



Supplementary Figure 1. Forest plot of treatment differences on the standard normal scale for ACR response at weeks 12–16 among bDMARD-naïve patients with active PsA (ixekizumab 80 mg Q4W as the reference).




ACR = American College of Rheumatology; bDMARD = biologic disease-modifying anti-rheumatic drug; BID = twice daily; BIW = twice weekly; IV = intravenously; PsA = psoriatic arthritis; QxW = every x weeks; SC = subcutaneously.

Supplementary Figure 2. Forest plot of odds ratios for PsARC at weeks 12–16 among bDMARD-naïve patients with active PsA (ixekizumab 80 mg Q4W as the reference).



bDMARD = biologic disease-modifying anti-rheumatic drug; BID = twice daily; BIW = twice weekly; IV = intravenously; PsA = psoriatic arthritis; PsARC = Psoriatic Response Criteria; QxW = every x weeks; SC = subcutaneously.

Supplementary Figure 3. Forest plot of treatment differences on the standard normal scale for PASI at weeks 12–16 among bDMARD-naïve patients with active PsA (ixekizumab 80 mg Q4W as the reference).



bDMARD = biologic disease-modifying anti-rheumatic drug; BID = twice daily; BIW = twice weekly; IV = intravenously; PASI = Psoriasis Area and Severity Index; PsA = psoriatic arthritis; QxW = every x weeks; SC = subcutaneously.